Welcome to Arrien Pharmaceuticals

Arrien Pharmaceuticals is a clinical stage drug discovery company focused on developing small molecules targeting protein kinase signaling, nuclear hormone receptor and immuno-oncology/checkpoint pathway targets for treating human cancers, autoimmune and neurodegenerative diseases.
The company successfully applied its proprietary platform "FIELDS" technology and discovered two clinical candidates and others in development:

  • ARN-6039 (currently known as BOS-172767), an orally available, selective small molecule inhibitor of ROR-γt (retinoic acid-related orphan nuclear hormone receptor gamma-t) being investigated in a Phase 1 clinical trials. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. ARN-6039 was partnered with Boston Pharmaceuticals in 2017. A Phase 2 clinical POC studies in psoriasis and other autoimmune indications planed for Q3 2019. Our partner Boston Pharmaceuticals advancing several of their compounds in clinical trials that were the outcome of discovery collaborations and the responsibility for developing ARN-6039/BOS-172767 is with our partner.
  • ARN-3261, an orally available small molecule inhibitor of SIK2 (Salt Inducible Kinase 2) to be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. An IND being approved to initiate the Phase 1a/1b trials beginning of Q2 2019.
  • ARN-0953, an orally available, highly selective small molecule inhibitor of the MELK (Maternal Embryonic Leucine Zipper Kinase) and FLT3/CD135 (FMS like Tyrosine Kinase 3) specific kinases. ARN-0953 currently in IND enabling studies and to be investigated in Phase 1 clinical trials for AML and other solid tumors (TNBC, GBM & Lung cancers) in Q1 2020.
  • ARN-0894, an orally available, small molecule agonist of stimulatory checkpoint pathway targets responsible for costimulatory signals. Several agonist mAbs have been developed to engage with these checkpoint pathway targets and ARN-0894 currently in pre-clinicals stage of development. ARN-0894 discovered to potentially enhance the anti-tumor immunity though co-stimulatory mechanism. IND enabling studies to follow the initiation of Phase 1 clinical trials in Q3 2020.

Arrien Pharmaceuticals competitive and unique drug discovery and development approaches coupled with experienced scientific, clinical and business team who are expertise in multidisciplinary areas of kinase signaling, nuclear hormone receptor and checkpoint pathways and technology has been the key to company's success since its incorporation in 2011.

Read More..

Latest News

  • 28January
    2019

    Salt Lake City - January 28, 2019: Arrien Pharmaceuticals successfully completed ARN-3261 IND (Investigational New Drug) enabling studies demonstrating significant efficacy and disease control in disease non-clinical models of Ovarian Cancers. In Sep 2018, the U.S. Food and Drug Administration accepted our IND application to begin a Phase 1 clinical trial on ARN-3261 POC trials. ARN-3261 is an agent for the treatment of Women Cancers and we are in the process of initiating clinical trials in Q2 2019.

  • 07January
    2019

    Salt Lake City - January 07, 2019: Arrien Pharmaceuticals management participated in 37th Annual J.P Morgan Healthcare Conference. January 7-10, 2019. Westin St. Francis Hotel, San Francisco, CA.

     

  • 03August
    2018

    Salt Lake City - Aug 03, 2018: Arrien Pharmaceuticals Management participated and presented at Biocentury. The 25th Annual “News Maker in the Biotech Industry, September 7, 2018, New York City.
     

  • 05June
    2018

    Salt Lake City – June 5, 2018: Arrien Pharmaceuticals Management participated in Bio International Conference Boston, June 5-7, 2018.
    http://convention.bio.org/

  • 04June
    2018

    Salt Lake City – June 4, 2018: Arrien Pharmaceuticals Management participated in RESI Conference (Redefining Early Stage Investments), Boston, MA on June 4, 2018.
    http://www.resiconference.com/resi-boston-summer-2018-photos

  • 09February
    2018

    Salt Lake City - February 09, 2018: Arrien Pharmaceuticals Management participated in American Academy of Dermatology (AAD) Annual Meeting in San Diego, Calif., on Feb. 16-20, 2018.

     

  • 08January
    2018

    Salt Lake City: January 08, 2018: Arrien Pharmaceuticals management participated in 36th annual J. P. Morgan Health Care Conference | January 8-11, 2018 at the Westin in San Francisco, California, USA.
     

  • 11November
    2017

    Salt Lake City: November 11, 2017: Arrien Pharmaceuticals management participated in SfN’s 47th annual meeting, Neuroscience 2017, the world’s largest neuroscience conference | November 11-15 at the Walter E. Washington Convention Center in Washington DC.
    https://www.sfn.org

  • 28June
    2017

    Salt Lake City: June 28, 2017, 9.00 AM EST: Arrien Pharmaceuticals announces a worldwide license agreement for ARN-6039, a clinical stage oral ROR-γt inverse agonist for the treatment of psoriasis and potentially other autoimmune disorders.
    http://www.businesswire.com/news/home/20170628005166/en/Arrien-Pharmaceuticals-Announces-Worldwide-License-Agreement-ARN-6039

  • 11January
    2017

    Salt Lake City: January 11, 2017
    Arrien Pharmaceuticals Management to participated in 2017 AAD (American Academy of Dermatology) Annual Meeting on March 03-07, 2017 in Orlando, Florida.
    https://www.aad.org/meetings/annual-meeting

  • 11January
    2017

    Salt Lake City: January 11, 2017
    Arrien Pharmaceuticals Management to participated in AACR Annual Meeting to be held on April 1-5, 2017 in Washington, D.C.
     

  • 09January
    2017

    Salt Lake City: January 09, 2017
    Arrien Pharmaceuticals management participates in the J.P. Morgan 35th Annual Healthcare Conference on 9 - 12 January 2017 in San Francisco, CA, USA.

  • 08January
    2017

    Salt Lake City: January 08, 2017
    Arrien Pharmaceuticals Management participated in “The 4th Annual Dermatology Summit” was held in San Francisco, California on January 08, 2017.
    http://www.dermsummit.com/2017

  • 03October
    2016

    Salt Lake City: October 03, 2016: Arrien Pharmaceuticals management participates Bio INVESTOR Forum at San Francisco, California on October 18-9 2016.
    https://www.bio.org/events/bio-investor-forum

  • 01August
    2016

    Salt Lake City: Aug 1, 2016: Arrien Pharmaceuticals pleased to announce that the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Selection Committee has accepted the abstract titled "Development of ARN-6039, an RORyt/IL-17-TH17 specific agent for treatment of multiple sclerosis and evaluation of phase 1 trials in normal controls" for a presentation at the Annual Meeting to be held in London, England on 14-17 September 2016.

    Session Title: Poster Session 2
    Session Date: Friday, 16 September 2016
    Session Time: 15:30-17:00

  • 01June
    2016

    Arrien Pharmaceuticals Management to participate and present the company’s pipeline overview at BIO International Convention on June 6-9, 2016 | Moscone Center, San Francisco, CA.
    http://convention.bio.org/2016

  • 23May
    2016

    Arrien Pharmaceuticals management to participate 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

  • 16May
    2016

    Arrien Pharmaceuticals initiated the First in Human (FIH) Phase I Clinical trials for Safety, Tolerability, and Pharmacokinetic Profile of ARN-6039 in health subjects on May16, 2016.

  • 09May
    2016

    Arrien Pharmaceuticals to initiate the Phase I Clinical trials for Safety, Tolerability, and Pharmacokinetic Profile of ARN-6039 in health subjects in May 2016.

  • 29April
    2016

    Arrien Pharmaceuticals successfully completed ARN-6039 IND enabling studies demonstrating significant efficacy and disease control in disease models of Multiple Sclerosis (MS).
    In April 2016, the U.S. Food and Drug Administration accepted our Investigational New Drug application to begin a Phase 1 clinical trial on ARN-6039 for Safety, Tolerability, and Pharmacokinetic Profile. ARN-6039 an agent for the treatment of MS and we are in the process of initiating clinical trials on May 2016.

  • 18April
    2016

    Arrien Pharmaceuticals management participated and presented pre-clinical data on ROR/IL-17 program at the 68th AAN (American Academy of Neurology) Annual Meeting on April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada.
    https://www.aan.com/conferences/2016-annual-meeting

  • 05November
    2015

    Arrien Pharmaceutical Management participated in “Annual BioUtah Life Sciences Summit Meeting” was held on November 5, 2015 at Hilton Hotel in Salt Lake City, UT, USA.
    http://www.bioutah.org

  • 07May
    2015

    Arrien Pharmaceuticals management participated and presented at the 10th Protein Kinases in Drug Discovery Conference, which will take place on May 7-8, 2015 in Berlin, Germany.

  • 18April
    2015

    Arrien Pharmaceuticals management participated at the 67th AAN (American Academy of Neurology) Annual Meeting on April 18-25, 2015, at the Walter E. Washington Convention Center in Washington, DC.

  • 09September
    2014

    Arrien Pharmaceuticals today announced that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,791,112 B2; July 29, 2014.

     
    The term of the patent is 20 years from the earliest effective filing data March 2012, claim pharmaceutical compositions matter comprising of pre-clinical stage ORS-1104 and related compounds useful as protein kinase inhibitors, specifically LRRK2 (Leucine-Rich Repeat Kinase-2) for the treatment of Parkinson's Disease, Alzheimer's Disease, Down's Syndrome, Huntington's Disease, other Neurodegenerative and Central Nervous System disorders.
     

  • 01September
    2014

    Arrien Pharmaceuticals pleased to announce that the American College of Rheumatology (ACR) Selection Committee has accepted the abstract titled "Discovery of ARN-4079 - a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis" for a presentation at the 2014 ACR/ARHP Annual Meeting, to be held in Boston, MA on November 14-19, 2014.
     
    The schedule for our presentation is as follows: 
    Session Type/Number: Poster/1459
     
    Session Name: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis 
     
    Presentation Time: Monday, November 17, 2014 at 9:00-11:00 AM
     
    Location: Boston Convention and Exhibit Center - Exhibit Hall B 

  • 10July
    2014

    Arrien Pharmaceuticals Management will be participating in American College of Rheumatology (ACR) 2014 Annual Meeting schedule to be held on November 14-19, 2014 in Boston, Massachusetts.

  • 27June
    2014

    Arrien Pharmaceuticals Management participated in The USA-India Chamber of Commerce 2014 meeting on “US-India BioPharma & Healthcare Summit” was held on Friday June 27th, 2014 at the Marriott Cambridge, Massachusetts, 02142, USA.

  • 05April
    2014

    Arrien Pharmaceuticals Scientific team first-time presents preclinical data showing ARN-3236 inhibits clinically relevant target SIK2 at AACR 2014.

    Salt Lake City, UT., April 3, 2013 - Arrien Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of an abstract covering internally funded SIK2 inhibitor data for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014, April 5-9 In San Diego, CA.
     
    Title: Highly potent and orally available SIK2 inhibitors block growth of human ovarian cancer cells in culture and xenografts
    Abstract Number: 749
    Session ID: Experimental and Molecular Therapeutics 3
    Session Date and Time: Sunday Apr 6, 2014 1:00 PM - 5:00 PM
    Location: Hall A-E, Poster Section 31
    Read More..

  • 29March
    2014

    Arrien Pharmaceuticals Management participated in The EPPIC 2014 Annual Conference “Interdisciplinary Innovations in Life Sciences” was held on Saturday, March 29th, 2014 at the Westin SFO Airport, 1 Old Bayshore Highway, Millbrae, CA, 94030, USA.

  • 06November
    2013

    Arrien Pharmaceuticals Management participated in entrepreneurial track speaker session of “Annual BioUtah Summit Conference” was held on November 6, 2013 at the Grand America Hotel in Salt Lake City, UT, USA.

  • 19September
    2013

    Arrien Pharmaceuticals Management participating “Rocky Mountain Life Science Investor & Partnering Conference” on September 18-19, 2013 at Ritz-Carlton, Denver, CO, USA.

  • 22April
    2013

    Arrien Pharmaceuticals Management participated and presented the company\'s business and scientific overview at BIO International Convention on April 22-25th at McCormick Place Chicago, Illinois, USA.

  • 20March
    2013

    Arrien Pharmaceuticals Management participated and presented the company's business and scientific overview at The Life Sciences and Healthcare Venture Summit, hosted by youngStartup Ventures, on March 20th at Digital Sandbox, New York City, USA.

  • 06November
    2012

    Arrien Pharmaceuticals and Laboratory of Cell Signaling and Metabolic Disease, National Institute of Biomedical Innovation (NIBIO) Osaka, Japan headed by Dr. Hiroshi Takemori, PhD have signed a sponsored research collaboration agreement to study the role of SIK2 and SIK3 protein targets; its clinical relevance, association in Cancer, Diabetes diseases and inhibition by target specific SIK2 and SIK3 inhibitors.

  • 16August
    2012

    The lead back-up candidate ORS-1104 is now advanced into IND enabling stage of development for Parkinson's disease.

  • 05May
    2012

    ORS-1006 originally nominated candidate; an extensive pre-clinical toxicology and pharmacology studies were conducted for Parkinson’s disease indication to be progressed latter this year. Currently the back-up candidate compound ORS-1104 entered into pre-clinical development has been shown to be highly potent, selective and is effective in mouse models of PD.

  • 05May
    2012

    Arrien Pharmaceuticals Management and Scientific Advisory members participating and presenting at Next-Gen Kinase Inhibitors Conference taking place in June 4-6, 2012 at Boston, Cambridge, MA.

  • 14December
    2011

    Arrien Pharmaceuticals Management participating and presenting at Molecular Med TRI-CON - Partnering Forum, taking place February 19 - 20, 2012 in San Francisco, CA.

  • 24October
    2011

    Dr. Philip LoGrasso appointed to the Scientific Advisory Board for CNS/Neurodegenerative Diseases.
    Read More..

  • 03October
    2011

    Arrien Pharmaceuticals and MD Anderson Cancer Center of The University of Texas have signed a sponsored research collaboration agreement to conduct the cellular and in vivo efficacy of SIK2 inhibitors discovery by Arrien Pharmaceuticals scientists for treating Ovarian Cancer.  Robert C. Bast, Jr., M.D, Vice President for Translational Research and his team discovered new Ser/Thr kinase target SIK2 and the study was published in Cancer Cell, 2010, 18(2), 109-121. Their published key findings on Salt Inducible Kinase 2 (SIK2) suggests that the overexpressed/increased SIK2 levels in approximately 30% of ovarian cancers and were associated with poorer survival in women with the disease. Inhibition of SIK2 with inhibitors is effective in treating Ovarian Cancer and halt the cancer growth.

  • 12September
    2011

    Arrien Pharmaceuticals Founder\'s closes $2.0 Million Series A Financing. Read More..

  • 06September
    2011

    Arrien Pharmaceuticals Management participating in 4th CNS Partnering and Deal-making • Sep 22-23, 2011 • San Francisco, CA, USA

  • 01July
    2011

    Arrien Pharmaceuticals secures initial funding from company founders and initiated its New Drug Discovery (NDD), Medicinal Chemistry and Screening research activities on several of its pipeline programs.

  • 01July
    2011

    Arrien Pharmaceuticals, a small molecule Drug Discovery Company entered into an agreement with Oros Pharmaceuticals Pvt. Ltd (India) a  Neurodegenerative/CNS Drug Discovery Company to combine the discovery efforts to advance the Oros Pipeline.

  • 01July
    2011

    Arrien Pharmaceuticals, a small molecule Drug Discovery Company based in USA entered into an agreement with Alveus Pharmaceuticals Pvt. Ltd (India) for all of its early Medicinal Chemistry/Discovery Research Services.
    Alveus Pharmaceuticals, a Contract Research Organization (CRO) offers custom synthesis services for the Pharmaceutical/Biotechnology industries, research institutes and Universities for their drug discovery research and development process.

  • 06June
    2011

    Arrien Pharmaceuticals Management participated in World Pharma Congress (WPC) Drug Discovery Summit meeting held on June 7-9, 2011 at Philadelphia on Targeting Alzheimer\'s and Parkinson\'s disease.

More News

Our Pipeline

Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases.

Therapeutic Areas

Oncology Programs

Arrien Pharmaceuticals is pursuing several clinically relevant druggable targets particularly kinases, stimulatory and inhibitory immune checkpoint regulators with small molecules for the treatment of different cancers. The lead investigational agents; ARN-3261, ARN-0953 and ARN-0894 that are currently in various stages of development...

Other Programes

Arrien Pharmaceutical has discovered and advanced the development of small molecule antagonist ARN-6039 targeting Retinoic acid-related orphan nuclear receptor gt (RORgt)/RORg. RORgt is the key transcription factor and is the master regulator of human Th17 cells, a unique subset of CD4+T cells.

Arrien Pharmaceuticals applying its proprietary FIELDS technology to identify novel, Med-Chem tractable hits into high ligand efficient leads derived from core scaffold binding patterns with in the target protein active site hot-spots